Reaction
Immune-Mediated Adverse Reaction reporting signals
As of the last recalculation, Immune-Mediated Adverse Reaction appears in 1,442 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 267.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 831 | 267.7 | 269.8 |
| Ipilimumab | 110 | 39.7 | 39.8 |
| Durvalumab | 52 | 38.2 | 38.3 |
| Nivolumab | 165 | 27.7 | 27.7 |
| Atezolizumab | 64 | 24.8 | 24.9 |
| Pemetrexed Disodium | 55 | 21.6 | 21.7 |
| Pemetrexed | 30 | 20.6 | 20.6 |
| Paclitaxel (Aibumin-Bound) | 68 | 12.5 | 12.5 |
| Carboplatin | 100 | 12.1 | 12.1 |
| Paclitaxel | 69 | 10.5 | 10.5 |
| Bevacizumab | 83 | 10.2 | 10.2 |
| Faricimab | 5 | 8.9 | 8.9 |
| Lenvatinib | 17 | 7.6 | 7.6 |
| Gemcitabine | 19 | 7.0 | 7.0 |
| Gemcitabine Hydrochloride | 25 | 6.9 | 6.9 |
| Axitinib | 9 | 6.7 | 6.7 |
| Doxorubicin Hydrochloride | 15 | 6.7 | 6.7 |
| Cabozantinib | 15 | 4.5 | 4.5 |
| Ledipasvir And Sofosbuvir | 6 | 4.5 | 4.5 |
| Olaparib | 6 | 4.2 | 4.2 |
| Aflibercept | 6 | 2.8 | 2.8 |